| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Departments of Epidemiology [X. W., Y. Z., Q. V. W., M. R. S.], Clinical Cancer Prevention [S. M. L.], Biomathematics [J. J. L.], and Thoracic and Head and Neck Medical Oncology [M. T., W. K. H.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Oral premalignant lesions (OPLs) are related to tobacco use and mark individuals at high risk for oral cancer development. Increased mutagen sensitivity as measured by an in vitro mutagen challenge assay has been shown to be a risk factor for upper aerodigestive tract cancers. In this case control study, we used two assays with mutagens relevant to tobacco exposure (benzo[a]pyrene diol epoxide (BPDE) and bleomycin) to see whether sensitivity to these mutagens could be used as biomarkers for assessing risk of premalignant lesions. Furthermore, we evaluated whether 3p21.3 is a molecular target of BPDE damage in lymphocytes of patients with OPLs. There were 82 patients with OPLs and 89 healthy controls frequency matched to the cases on age, sex, ethnicity, and smoking status. These subjects’ lymphocytes were treated in two separate experiments with either 2 µM BPDE for 24 h or 0.03 units/ml bleomycin for 5 h, and the frequency of induced chromatid breakage in Giemsa-stained preparations was determined. BPDE-induced 3p21.3 aberrations were scored by fluorescent in situ hybridization technique in 1000 interphases/sample. We found that the mean BPDE-induced chromatid breaks per cell were higher in cases than controls (1.05 ± 0.40 and 0.55 ± 0.27, respectively; P < 0.01). Similar results were evident with bleomycin-induced chromatid breaks per cell (0.78 ± 0.37 and 0.57 ± 0.31, respectively; P < 0.01). After adjusting for age, sex, ethnicity, and smoking status, significantly elevated odds ratios (95% confidence interval) for OPL risk were noted for BPDE sensitivity [12.96 (5.51, 30.46)] and bleomycin sensitivity [3.33 (1.64, 6.77)]. When subjects were categorized into quartiles of the number of breaks per cell, a dose response was observed for both assays. The adjusted odds ratios for subjects with increasing numbers of breaks per cell in quartiles were 2.34, 9.14, and 54.04 for BPDE sensitivity and 1.92, 3.33, and 7.15 for bleomycin sensitivity, respectively. Subjects sensitive to both mutagens had a 50-fold increased risk for OPLs. In addition, there were significantly more BPDE-induced chromosome aberrations at the 3p21.3 locus in cases (51.13/1000) than in controls (40.93/1000; P < 0.0001). However, no such difference was observed for 3q13, a control locus. BPDE-induced 3p21.3 aberrations were associated with an elevated risk for OPLs of 6.08 (2.57, 14.4). The degree of BPDE sensitivity at 3p21.3 and risk for OPLs increased in a dose-dependent manner. In summary, BDPE sensitivity and bleomycin sensitivity appear to be individually and jointly associated with elevated risk of OPLs. Furthermore, 3p21.3 may be a molecular target of BPDE in OPLs. This is the first study to examine mutagen sensitivity in a premalignant condition. The next step is to correlate these findings in surrogate (lymphocyte) tissue with molecular events in the target tissue.
This article has been cited by other articles:
|
|
 |
|
  M. Reiter, P. Baumeister, S. Zieger, and U. Harreus Chromosomal Alterations and Mutagen Sensitivity in Human Mucosal Cells of the Oropharynx and Lymphocytes Caused by BPDE Cancer Genomics Proteomics, September 1, 2009; 6(5): 247 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gu, Y. Horikawa, M. Chen, C. P. Dinney, and X. Wu Benzo(a)pyrene Diol Epoxide-Induced Chromosome 9p21 Aberrations Are Associated with Increased Risk of Bladder Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2445 - 2450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-E Wang, P. Xiong, H. Zhao, M. R. Spitz, E. M. Sturgis, and Q. Wei Chromosome Instability and Risk of Squamous Cell Carcinomas of Head and Neck Cancer Res., June 1, 2008; 68(11): 4479 - 4485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, M. R. Spitz, J. J. Lee, M. Huang, S. M. Lippman, and X. Wu Nucleotide Excision Repair Pathway Genes and Oral Premalignant Lesions Clin. Cancer Res., June 15, 2007; 13(12): 3753 - 3758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, J. Gu, and M. R. Spitz Mutagen Sensitivity: A Genetic Predisposition Factor for Cancer Cancer Res., April 15, 2007; 67(8): 3493 - 3495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Chao, C. C. Maley, X. Wu, D. C. Farrow, P. C. Galipeau, C. A. Sanchez, T. G. Paulson, P. S. Rabinovitch, B. J. Reid, M. R. Spitz, et al. Mutagen Sensitivity and Neoplastic Progression in Patients with Barrett's Esophagus: A Prospective Analysis. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1935 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Huang, M. R. Spitz, J. Gu, J.J. Lee, J. Lin, S. M.Lippman, and X. Wu Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions Carcinogenesis, October 1, 2006; 27(10): 2034 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Erdei, S.-J. Lee, Q. Wei, L.-E. Wang, Y.-S. Song, D. Bovbjerg, and M. Berwick Reliability of mutagen sensitivity assay: an inter-laboratory comparison Mutagenesis, July 1, 2006; 21(4): 261 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. El-Zein, M. B. Schabath, C. J. Etzel, M. S. Lopez, J. D. Franklin, and M. R. Spitz Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res., June 15, 2006; 66(12): 6449 - 6456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Chang, R. Komaki, R. Sasaki, Z. Liao, C. W. Stevens, C. Lu, F. V. Fossella, P. K. Allen, J. D. Cox, M. R. Spitz, et al. High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Non-Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy Clin. Cancer Res., April 15, 2005; 11(8): 2894 - 2898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman, J. Sudbo, and W. K. Hong Oral Cancer Prevention and the Evolution of Molecular-Targeted Drug Development J. Clin. Oncol., January 10, 2005; 23(2): 346 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Garnis, C. Baldwin, L. Zhang, M. P. Rosin, and W. L. Lam Use of Complete Coverage Array Comparative Genomic Hybridization to Define Copy Number Alterations on Chromosome 3p in Oral Squamous Cell Carcinomas Cancer Res., December 15, 2003; 63(24): 8582 - 8585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Sabichi, M.-F. Demierre, E. T. Hawk, C. E. Lerman, and S. M. Lippman Frontiers in Cancer Prevention Research Cancer Res., September 15, 2003; 63(18): 5649 - 5655. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
